How many clinical trials are studying Famitinib?

6 recruiting trials in our tracked data involve Famitinib.

What conditions is Famitinib being studied for?

In our tracked recruiting trials, Famitinib is being studied in trials for Breast Cancer, HER2-negative Breast Cancer, Advanced Breast Cancer.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 2 5 Phase 3 1

Condition	Trials
Breast Cancer · Famitinib for Breast Cancer	5
HER2-negative Breast Cancer · Famitinib for HER2-negative Breast Cancer	4
Advanced Breast Cancer	2
Breast Neoplasm	2
Hormone Receptor Positive Tumor	2
Triple Negative Breast Cancer (TNBC)	2
BRCA-Mutated Breast Carcinoma	1
Breast Tumors	1
Early-stage Breast Cancer	1
HER2-positive Breast Cancer	1
Hormone Receptor Negative Tumor	1
Locally Advanced Breast Cancer	1
Lung cancer	1
Metastatic Breast Cancer	1
Sarcomatoid Carcinoma of Lung	1

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
NCT04888429 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 8 locations
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
NCT06516289 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location